Stuart L. Silverman
#163,462
Most Influential Person Now
Stuart L. Silverman's AcademicInfluence.com Rankings
Stuart L. Silvermanphilosophy Degrees
Philosophy
#9516
World Rank
#13089
Historical Rank
Logic
#6490
World Rank
#8011
Historical Rank

Download Badge
Philosophy
Why Is Stuart L. Silverman Influential?
(Suggest an Edit or Addition)Stuart L. Silverman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Risk of new vertebral fracture in the year following a fracture. (2001) (1721)
- Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research (2007) (1562)
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. (2000) (1055)
- Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011) (915)
- Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. (2006) (694)
- The clinical consequences of vertebral compression fracture. (1992) (607)
- Fractures Attributable to Osteoporosis: Report from the National Osteoporosis Foundation (1997) (546)
- International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. (2008) (538)
- Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. (1996) (457)
- Obesity is not protective against fracture in postmenopausal women: GLOW. (2011) (451)
- A systematic review of persistence and compliance with bisphosphonates for osteoporosis (2007) (443)
- The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group (2014) (414)
- Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. (2008) (398)
- Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial (2008) (397)
- Incidence of atypical nontraumatic diaphyseal fractures of the femur (2012) (378)
- The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. (2001) (345)
- Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention (2012) (342)
- Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. (2008) (326)
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (2005) (323)
- Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society (2010) (323)
- From randomized controlled trials to observational studies. (2009) (320)
- A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis (2012) (295)
- Deterioration in Quality of Life Following Hip Fracture: A Prospective Study (2000) (280)
- Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. (2009) (268)
- Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. (1988) (252)
- Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. (1996) (213)
- Relationship of Weight, Height, and Body Mass Index With Fracture Risk at Different Sites in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (211)
- Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study (2006) (183)
- Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. (2009) (181)
- Salmon calcitonin: a review of current and future therapeutic indications (2008) (178)
- Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. (1996) (155)
- Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study (2011) (153)
- Therapeutic options (1991) (129)
- Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF (2013) (127)
- National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges (2012) (126)
- The Utility and Limitations of FRAX: A US Perspective (2010) (118)
- The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures (2012) (115)
- Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data (2009) (115)
- The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture (2013) (114)
- Increasing hip fracture incidence in California Hispanics, 1983 to 2000 (2004) (107)
- Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry (2008) (107)
- When, Where and How Osteoporosis-Associated Fractures Occur: An Analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2013) (106)
- Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures (2011) (102)
- Osteonecrosis of the Jaw: More Research Needed (2006) (94)
- Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women (2012) (92)
- International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates (2017) (91)
- The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. (2009) (89)
- The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design (2009) (88)
- Individualizing osteoporosis therapy (2012) (87)
- Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire. (1998) (86)
- Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. (2006) (83)
- Oral bisphosphonate compliance and persistence: a matter of choice? (2010) (81)
- Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2010) (81)
- Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. (2011) (80)
- The Analgesic Role of Calcitonin Following Osteoporotic Fracture (2002) (78)
- Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS (2018) (77)
- Osteonecrosis of the jaws and bisphosphonates (2008) (76)
- A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture (2015) (75)
- Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. (2009) (74)
- Effect of Bone Density Information on Decisions About Hormone Replacement Therapy: A Randomized Trial (1997) (73)
- The Comparative Burden of Chronic Widespread Pain and Fibromyalgia in the United States (2016) (72)
- Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce (2009) (68)
- Quality-of-life issues in osteoporosis (2005) (66)
- Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. (2005) (63)
- Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study (2013) (61)
- The role of socioeconomic status on hip fracture (2006) (59)
- Primary non-adherence to bisphosphonates in an integrated healthcare setting (2013) (59)
- Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study (2014) (58)
- Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide. (2004) (57)
- Fibromyalgia and Chronic Pain Syndromes (2016) (56)
- Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions (2008) (56)
- Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. (2018) (52)
- Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (52)
- The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis (2000) (50)
- The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women. (2003) (48)
- Bone loss or lost bone: Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss (2009) (48)
- Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with Osteoporosis (2004) (47)
- The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results (2013) (47)
- Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) (2007) (47)
- Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. (2007) (47)
- Obesity, Health-Care Utilization, and Health-Related Quality of Life After Fracture in Postmenopausal Women: Global Longitudinal Study of Osteoporosis in Women (GLOW) (2014) (45)
- Identifying Fibromyalgia‐Associated Symptoms and Conditions from a Clinical Perspective: A Step Toward Evaluating Healthcare Resource Utilization in Fibromyalgia (2010) (45)
- Thrombocytopenia and intravenous heroin use. (1978) (44)
- New Selective Estrogen Receptor Modulators (SERMs) in Development (2010) (42)
- Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates (2012) (42)
- Review of adherence to medications for the treatment of osteoporosis (2006) (42)
- What’s in a name? What constitutes the clinical diagnosis of osteoporosis? (2012) (41)
- Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW) (2012) (41)
- Quality of life measurement in osteoporosis. (1997) (41)
- Rationale for the potential use of calcitonin in osteoarthritis. (2005) (39)
- Compliance and persistence with osteoporosis therapies (2008) (39)
- Recent developments in bisphosphonate therapy. (2007) (39)
- The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis* (2009) (39)
- Toward characterization and definition of fibromyalgia severity (2010) (38)
- An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study* (2006) (38)
- Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid (2010) (38)
- Fracture risk following intermission of osteoporosis therapy (2019) (37)
- Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. (2012) (36)
- Compliance and persistence with osteoporosis medications: A critical review of the literature (2010) (36)
- An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis (2012) (36)
- Commentary: The Five Ws of a Fracture Liaison Service: Why, Who, What, Where, and How? In Osteoporosis, We Reap What We Sow (2013) (36)
- Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial (2012) (34)
- Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women (2012) (33)
- Sclerostin (2010) (33)
- Antibodies to Epstein—Barr Viral Antigens in Early Rheumatoid Arthritis (1981) (32)
- International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study (2014) (32)
- Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies (2007) (32)
- Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis (2013) (32)
- Risk of Severe Gastrointestinal Events in Women Treated with Monthly Ibandronate or Weekly Alendronate and Risedronate (2009) (31)
- Health-related quality of life in osteoporosis clinical trials. The Osteoporosis Quality of Life Study Group. (1993) (30)
- Primary Care Physicians’ Perceptions of the Challenges and Barriers in the Timely Diagnosis, Treatment and Management of Fibromyalgia (2011) (28)
- Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies (2013) (28)
- Glucocorticoid-induced osteoporosis: a cross-sectional study (1991) (28)
- Tolerability of risedronate in postmenopausal women intolerant of alendronate (2001) (27)
- Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS (2018) (27)
- An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX® (2013) (27)
- A musculoskeletal syndrome in intravenous heroin users: association with brown heroin. (1977) (26)
- Glucocorticoid-induced osteoporosis (2009) (25)
- Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group (2016) (25)
- Validation of the Osteoporosis-Specific Morisky Medication Adherence Scale in long-term users of bisphosphonates (2014) (24)
- Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. (2014) (24)
- Calcitonin : Management of osteoporosis, 1997 (1997) (24)
- Osteoporosis Self-management:Choices For Better Bone Health (2004) (24)
- Evaluation of a Multimodal, Direct‐to‐Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial (2018) (24)
- Anabolic Therapies (2010) (23)
- Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products (2016) (22)
- Redefining osteoporosis treatment: Who to treat and how long to treat. (2006) (22)
- Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective (2015) (22)
- Impact of fractures on quality of life in patients with osteoporosis: a US cross-sectional survey (2019) (22)
- Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis (2007) (21)
- Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. (2020) (20)
- Real‐World Evaluation of Health‐Care Resource Utilization and Costs in Employees with Fibromyalgia Treated with Pregabalin or Duloxetine (2011) (20)
- The importance of aspects of treatment for fibromyalgia (fibrositis). Differences between patient and physician views. (1990) (20)
- Health-related quality of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. (2011) (19)
- Bisphosphonate use in conditions other than osteoporosis (2011) (19)
- Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. (2009) (19)
- Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double‐Blind Randomized Clinical Trial of Efficacy and Safety (2014) (18)
- Sensitivity and specificity of radiographic characteristics in atypical femoral fractures (2016) (18)
- Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy (2013) (18)
- Improved GI Tolerability with Monthly Ibandronate in Women Previously Using Weekly Bisphosphonates (2009) (18)
- Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies (2010) (18)
- Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study (2005) (18)
- Healthy users, healthy adherers, and healthy behaviors? (2011) (17)
- The impact of 'best-practice' patient care in fibromyalgia on practice economics. (2012) (17)
- Rachitic syndrome after disodium etidronate therapy in an adolescent. (1994) (16)
- Occasional Review: Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis (1995) (16)
- Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine (2010) (16)
- Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study (2018) (16)
- Selecting patients for osteoporosis therapy (2006) (15)
- Measuring health-related quality of life (HRQOL) in osteoporotic males using the Male OPAQ (2012) (15)
- Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression (2009) (14)
- Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies (2018) (14)
- Electronic medical record data to identify variables associated with a fibromyalgia diagnosis: importance of health care resource utilization (2015) (13)
- Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication (2018) (13)
- Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US (2016) (13)
- Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy. (2014) (13)
- The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. (2010) (12)
- New therapies for osteoporosis: Zoledronic acid, bazedoxifene, and denosumab (2009) (12)
- Management of corticosteroid-induced osteoporosis: A clinician's perspective (1992) (12)
- Adherence to medications for the treatment of osteoporosis. (2006) (12)
- A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): Rationale, design, and uptake of online study intervention material (2016) (12)
- Selecting Patients for Osteoporosis Therapy (2009) (11)
- Harmonization of commercial assays for PINP; the way forward (2020) (11)
- Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study (2010) (11)
- Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function (2014) (10)
- Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data (2011) (10)
- Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records (2015) (9)
- Self-perception of fracture risk: what can it tell us? (2017) (9)
- Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. (2013) (9)
- Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan (2021) (8)
- The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy (2016) (7)
- Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women (2021) (7)
- Identification of a potential fibromyalgia diagnosis using random forest modeling applied to electronic medical records. (2015) (7)
- Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications? (2018) (7)
- Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? (2007) (6)
- Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment (2020) (6)
- Effect of Baseline Characteristics on the Pain Response to Pregabalin in Fibromyalgia Patients with Comorbid Depression (2018) (6)
- Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United States (2016) (6)
- Development of the osteoporosis assessment questionnaire—physical function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function (2013) (6)
- Measuring Osteoporosis Quality: The Work of the Joint Commission (2013) (5)
- Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study (2013) (5)
- Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. (2014) (5)
- New bone density report format influences patient compliance in filling prescriptions for osteoporosis (2002) (5)
- Health-related quality of life in osteoporosis clinical trials urinary calcium loss (2005) (5)
- Bisphosphonate drug holidays: we reap what we sow (2016) (5)
- Selecting Patients for Osteoporosis Therapy (2007) (4)
- Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study (2014) (4)
- Comparison of FRAX Scores of Southern California Females of Mexican Descent Using US Hispanic and Mexico Database (2011) (4)
- A NEW AND MORE ACCURATE TECHNIC FOR INJECTING THE SUPERIOR MAXILLARY DIVISION (1923) (4)
- Failure to perceive increased risk of fracture in women aged 55 years and older. The global longitudinal study of osteoporosis in women (2009) (4)
- Efficient practices associated with diagnosis, treatment and management of fibromyalgia among primary care physicians. (2011) (4)
- Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures (2011) (4)
- FRACTURE PATTERNS WITH SELECTIVE SEROTONIN RECEPTOR INHIBITOR, PROTON PUMP INHIBITOR AND GLUCOCORTICOIDS USE IN GLOW (2014) (3)
- Bisphosphonates and atypical femoral fractures. (2010) (3)
- Identifying Individuals at Risk for Fracture in Guatemala (2011) (3)
- Risedronate treatment of postmenopausal women with low bone mass: Preliminary data (2006) (3)
- Compliance and persistence with osteoporosis therapies: we can do better (2007) (3)
- Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis (2015) (3)
- Individualizing osteoporosis medications (2014) (3)
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 Year results from the MOBILE study (Annals of the Rheumatic Diseases (2006) 65, (654-661)) (2008) (3)
- Lessons from osteoporosis clinical trials (2006) (3)
- Is Denosumab Cost-Effective Compared To Oral Bisphosphonates For The Treatment Of Male Osteoporosis (Mop) In Sweden? (2013) (2)
- Evaluation of Risk for Osteoporotic Fracture (2008) (2)
- Fracture efficacy of monthly ibandronate and weekly bisphosphonate therapy: a retrospective cohort study (2008) (2)
- Principles and practice of oral surgery (2)
- DENOSUMAB DECREASES CORTICAL POROSITY IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY (2011) (2)
- Bisphosphonate Therapy and Hip Fractures Within the Risedronate and Alendronate (REAL) Cohort Study: Subgroup With Prior Fracture (2008) (2)
- Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy (2010) (2)
- Erratum to: Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy (2013) (2)
- Nasal calcitonin (2007) (2)
- Oral Surgical Anatomy (1927) (1)
- Commentary: Measuring Quality of Care in Osteoporosis (2013) (1)
- Tolerability of monthly oral ibandronate in postmenopausal osteoporosis: 1-year results from the MOBILE Study (2004) (1)
- Efficacy and adverse event profile of monthly oral ibandronate during the first year of the mobile long-term extension study (2007) (1)
- PND5 COMPARISON OF DIRECT AND INDIRECT COSTS IN EMPLOYEES WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY TREATED WITH PREGABALIN OR DULOXETINE (2010) (1)
- World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2015): Poster Abstracts (2015) (1)
- The PREFER-US Study: An Evaluation of Patient Preferences for Osteoporosis Medications and Their Attributes (2006) (1)
- Multinational comparison of bone health in women 55 years of age and older The global longitudinal study of osteoporosis in women (2009) (1)
- Reports of Depression in Older Women with Osteoporosis (2014) (1)
- Increases in Bone Mineral Density with Once-Monthly Ibandronate: A Post Hoc Responder Rate Analysis of the MOBILE Study (2006) (1)
- (131) Transitions among chronic pain and fibromyalgia patients: results from a two-year observational fibromyalgia study in the United States (2015) (1)
- Drug utilization, clinical and economic outcomes of patients with osteoarthritis of the hip and/or knee treated with long-term use of traditional NSAIDs, topical NSAIDs, and COX-2 inhibitors (2022) (1)
- Chapter 17 – Calcitonin in the Treatment of Osteoporosis (2006) (1)
- The Status of Apicoectomy (1918) (1)
- Quality of Life in Patients with Osteoporosis: A Us Cross-Sectional Survey (2018) (1)
- Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture (2009) (1)
- Oral communications abstracts (2007) (0)
- Reply to the Letter by E. Czerwinski Regarding “The Utility and Limitations of FRAX: A US Perspective” (2012) (0)
- 211) Economic burden of chronic widespread pain and fibromyalgia in the US (2014) (0)
- Impact of efficient practices in the care of patients with fibromyalgia (2011) (0)
- THU0490 Temporal increases in side effect concerns of osteoporosis medications among women with previous fractures (2018) (0)
- Monthly ibandronate use is associated with a high percentage of BMD responders (2007) (0)
- Compliance Continuum and Fracture Risk Reduction with Bisphosphonate Treatment for Osteoporosis (2006) (0)
- Review Article Sclerostin (2010) (0)
- HOW WELL DOES SELF-PERCEPTION OF FRACTURE RISK RELATE TO FRACTURE PROBABILITY USING FRAX? FINDINGS FROM THE GLOW STUDY (2014) (0)
- Monthly Ibandronate Reduces Serum CTX Within Three Days of Treatment Initiation and Maintains a Monthly Pattern of Serum CTX Suppression (2008) (0)
- Suppression of Bone-Turnover Markers at 3 months is Maintained at 2 Years with Once-Monthly Ibandronate: MOBILE 2-Year Data (2006) (0)
- THU0472 Factors associated with readiness for adopting osteoporosis treatment change (2018) (0)
- Fragility Fractures and Health Status in a Multinational Cohort. The Global Longitudinal Registry of Osteoporosis in Women. (2008) (0)
- Risedronate is well tolerated in osteoporotic patients, including those older than 80 years (2002) (0)
- Pharmacology, Action and Toxicity of Various local Anesthetics (1920) (0)
- Osteoporosis, An Issue of Rheumatic Disease Clinics (2011) (0)
- A Musculoskeletal Syndrome in Intravenous Heroin Users (2020) (0)
- A Study of the Disputed Points in Local Anesthesia (1917) (0)
- POS0283 TREATMENT PATTERNS AND CLINICAL CHARACTERISTICS OF PATIENTS WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE TREATED WITH TRADITIONAL NSAIDS VS COX-2S: A REAL-WORLD STUDY OF COMMERCIALLY-INSURED PATIENTS (2021) (0)
- Comprar Osteoporosis, An Issue of Rheumatic Disease Clinics | Stuart L. Silverman | 9781455779918 | Saunders (2012) (0)
- Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE. (2005) (0)
- Association Between Adherence to Bisphosphonate Therapy and Reduced Nonvertebral Fracture Risk (2006) (0)
- Modelling of Serum CTX Levels with Daily and Monthly Oral Ibandronate (2006) (0)
- ANTIOSTEOPOROSIS MEDICATION USE REMAINS LOW AFTER FRACTURE BUT IS RELATED TO SELF PERCEIVED FRACTURE RISK: FINDINGS FROM THE GLOW STUDY (2014) (0)
- A Study of the Disputed Point in Local Anesthesia (1917) (0)
- Women are more persistent with monthly ibandronate versus weekly bisphosphonates (2007) (0)
- Atypical Neuralgias and Their Treatment (1924) (0)
- FRACTURE INCIDENCE IN OBESE POSTMENOPAUSAL WOMEN: THE GLOBAL STUDY OF OSTEOPOROSIS IN WOMEN (GLOW) (2012) (0)
- PMS20 Frequency of Initiating Pain Treatment with and Timing to Switching to Opioids Among Privately-Insured Patients with Osteoarthritis (2021) (0)
- DISTRIBUTION OF RISK FACTORS FOR FRACTURE IN WOMEN WITH AND WITHOUT A FRACTURE HISTORY: A REGIONAL COMPARISON. THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN (2008) (0)
- Once-monthly ibandronate improves GI tolerability in postmenopausal women transitioned from a weekly bisphosphonate (2007) (0)
- PMS40 Cost-Effectiveness of Denosumab for the Treatment of Male Osteoporosis (MOP) in the Elderly in Sweden (2012) (0)
- Further Studies in Trigeminal Neuralgia (1923) (0)
- Adverse Health Outcomes in Men with Osteoporosis (2010) (0)
- PMS3 Risk Factors Associated with Falls and Fractures Followed by Opioid Prescription among Privately-Insured Patients with Osteoarthritis (2021) (0)
- Failure to Perceive Increased Risk of Fracture in Women >= 55 Years. The Global Longitudinal Registry of Osteoporosis in Women (2008) (0)
- Fracture Rates With Monthly Oral Ibandronate and Weekly Bisphosphonates: The Evaluation of Ibandronate Efficacy (VIBE) Database Fracture Study (2008) (0)
- Understanding Physicians’ Perceptions of Patient-Identified Barriers to Osteoporosis Medication Initiation: A Cognitive Mapping Approach (2022) (0)
- 9 – Calcitonin Treatment in Postmenopausal Osteoporosis (2000) (0)
- Osteoporosis and the new absolute fracture risk algorithm (2008) (0)
- Selecting patients for osteoporosis therapy: the new WHO paradigm (2006) (0)
- Methodology questioned. (2008) (0)
- Salmon Calcitonin in the Treatment of Osteoporosis (2006) (0)
- Title New Selective Estrogen Receptor Modulators ( SERMs ) in Development Permalink (2010) (0)
- Adherence to Osteoporosis Therapies (2018) (0)
- PMS67 EXPERIENCE AND PREFERENCE-BASED EQ-5D-3L VALUE SET DERIVED FROM LONGITUDINAL DATA: RESULTS FROM THE INTERNATIONAL COSTS AND UTILITIES OF OSTEOPOROTIC FRACTURES STUDY (ICUROS) (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stuart L. Silverman?
Stuart L. Silverman is affiliated with the following schools: